Abstract: The present specification discloses a neuromodulation system comprising a transcranially mounted neuromodulation device and a stimulation control computing environment. The disclosed neuromodulation device comprising at least one ultrasound transducer and at least one EEG electrode and the disclosed stimulation control computing environment comprises a stimulation control unit and offline computing device, the disclosed stimulation control unit including associated systems and methods for controlling the neuromodulation device functionality using acoustic simulations performed on brain image data as well as methods and uses of such neuromodulation systems in modulating brain activity using focused ultrasound stimulation of the thalamus and thalamic sub regions during certain phases of slow wave brain oscillations in order to treat various neural-based disorders or conditions including sleep disorders.

Abstract: The present specification discloses a neuromodulation system comprising a transcranially mounted neuromodulation device and a stimulation control computing environment. The disclosed neuromodulation device comprising at least one ultrasound transducer and at least one EEG electrode and the disclosed stimulation control computing environment comprises a stimulation control unit and offline computing device, the disclosed stimulation control unit including associated systems and methods for controlling the neuromodulation device functionality using acoustic simulations performed on brain image data as well as methods and uses of such neuromodulation systems in modulating brain activity using focused ultrasound stimulation of the thalamus and thalamic sub regions during certain phases of slow wave brain oscillations in order to treat various neural-based disorders or conditions including sleep disorders.

Abstract: A head-wearable device is configured to hold at least one ultrasound transducer such that it is properly positioned for brain stimulation. Such a head-wearable device can help to ensure that the transducer makes sufficient contact with the user's head to allow for efficient ultrasound coupling. Each device may also ensure that the ultrasound transducer maintains the same orientation and position relative to the head across successive donning and doffing of the device.

Abstract: It relates to a compound of formula (I), or a pharmaceutically or veterinary acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically or veterinary acceptable salts, wherein R1, R2, and R3 are as defined herein, for use in the treatment or prevention of a neurological disease or condition which results in the destruction or degeneration of neurons, axons or myelin, wherein the treatment comprises: a) a first time period from 1 to 7 days, wherein the compound is administered once or several times to a subject in need thereof, and b) a second time period equal to or longer than 13 days, wherein the compound is not administered wherein the second time period takes place after the first time period and before the next administration of the compound.

Abstract: Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof, wherein: R1 R2 and R3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof, wherein R5 and R6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed.

Abstract: The present specification discloses a neuromodulation system comprising a transcranially mounted neuromodulation device and a stimulation control computing environment. The disclosed neuromodulation device comprising at least one ultrasound transducer and at least one EEG electrode and the disclosed stimulation control computing environment comprises a stimulation control unit and offline computing device, the disclosed stimulation control unit including associated systems and methods for controlling the neuromodulation device functionality using acoustic simulations performed on brain image data as well as methods and uses of such neuromodulation systems in modulating brain activity using focused ultrasound stimulation of the thalamus and thalamic sub regions during certain phases of slow wave brain oscillations in order to treat various neural-based disorders or conditions including sleep disorders.

Abstract: The present disclosure discusses systems and methods for identifying biomarkers that can help with the diagnosis, prognosis, and treatment choices of patients with neurodegenerative diseases. Diffusion based magnetic resonance imaging can often fail for patients with a neurodegenerative disease because parameters fractional anisotropy, mean diffusivity, and radial diffusivity are based on simple models that can fail in the presence of neurodegeneration, such as demyelination. The present disclosure discusses systems and methods that enhance dMRI images and enable tractography to be performed on images of a damaged nervous system. The damaged tracks identified by the present system can be used as a biomarker for the assessment of patients. In some implementations, the biomarkers are converted into clinical scales that can be used to compare patients to one another or over time.

Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Abstract: The present disclosure discusses systems and methods for identifying biomarkers that can help with the diagnosis, prognosis, and treatment choices of patients with neurodegenerative diseases. Diffusion based magnetic resonance imaging can often fail for patients with a neurodegenerative disease because parameters fractional anisotropy, mean diffusivity, and radial diffusivity are based on simple models that can fail in the presence of neurodegeneration, such as demyelination. The present disclosure discusses systems and methods that enhance dMRI images and enable tractography to be performed on images of a damaged nervous system. The damaged tracks identified by the present system can be used as a biomarker for the assessment of patients. In some implementations, the biomarkers are converted into clinical scales that can be used to compare patients to one another or over time.

Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Abstract: The present invention relates to a series of genes the expression of which is altered in subjects suffering multiple sclerosis with respect to healthy subjects or in subjects suffering multiple sclerosis with a good prognosis with respect to subjects suffering multiple sclerosis with a bad prognosis. A subset formed by 13 genes and two clinical variables which allows predicting the progress of a patient with a high reliability has been validated from an initial set of genes which showed said differential expression. From said expression values, the invention provides methods for predicting the progress of a patient diagnosed with multiple sclerosis from tables of conditional probability between the expression levels of a determined gene or group of genes and the probability that the patient has a good or bad prognosis of the disease.

Abstract: Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines.

Abstract: The present invention relates to combinations of 5?-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5?-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis.

Abstract: The present invention relates to the use of MTA, its pharmaceutically acceptable salts and/or prodrugs thereof as active ingredient in the manufacture of a medicament for the prevention or treatment of nerve cell death or damage, a neuroprotective medicament, a medicament for the regeneration of nerve cells, and a medicament for the prevention or treatment of a neurological or psychiatric disease. The present invention also relates to a method of prevention or treatment of nerve cell death or damage, a method of neuroprotection, a method of regenerating nerve cells and a method of prevention or treatment of a neurological or psychiatric disease.

Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Abstract: The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.

Abstract: The present invention relates to combinations of 5?-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5?-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis.